Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MZ-301
- Development stage
- Unknown
- Lead developer
- Maze Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MZ-301 is an orally bioavailable small molecule inhibitor of Apolipoprotein L1 (APOL1) currently in clinical development by Maze Therapeutics. The drug is designed to treat APOL1-mediated chronic kidney disease by potently blocking the pore-forming function of the APOL1 protein. High-risk genetic variants of APOL1 are known to cause podocyte cytotoxicity and lead to progressive renal decline; MZ-301 aims to mitigate this damage as a disease-modifying therapy. Preclinical data demonstrated that MZ-301 inhibits APOL1-dependent cytotoxicity in human podocytes and leads to a dose-dependent resolution of albuminuria in animal models of kidney disease.
02
Targets
APOL1 (Apolipoprotein L1)
Beyond the preview
Go deeper on MZ-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MZ-301.